Caption Management LLC Buys Shares of 163,076 Bicycle Therapeutics plc (NASDAQ:BCYC)

Caption Management LLC acquired a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 163,076 shares of the company's stock, valued at approximately $2,283,000. Caption Management LLC owned about 0.24% of Bicycle Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Barclays PLC grew its position in shares of Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares in the last quarter. Jane Street Group LLC grew its position in shares of Bicycle Therapeutics by 18.9% during the fourth quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock worth $336,000 after buying an additional 3,811 shares in the last quarter. Finally, Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth approximately $57,000. Hedge funds and other institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Trading Up 4.4%

Bicycle Therapeutics stock traded up $0.37 during trading on Monday, hitting $8.71. 116,488 shares of the company were exchanged, compared to its average volume of 349,005. The business's 50 day moving average is $8.44 and its 200 day moving average is $13.68. Bicycle Therapeutics plc has a 52 week low of $6.10 and a 52 week high of $28.67. The company has a market capitalization of $602.75 million, a P/E ratio of -2.65 and a beta of 1.60.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The business had revenue of $9.98 million during the quarter, compared to analysts' expectations of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Equities analysts expect that Bicycle Therapeutics plc will post -3.06 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on BCYC shares. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a research report on Monday, May 5th. Barclays lowered their price objective on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Royal Bank of Canada dropped their target price on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $25.00.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.